饮料通过向EZH2来增强前列腺癌的治疗效果
Chaehyun Yum1, Richard A Schaefer1, Rui Wang1
1Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Oncogenesis
|July 12, 2025
概括
EZH2在表观遗传上抑制HMGCS2,阻碍其在前列腺癌和乳腺癌中的抗癌作用. 来自HMGCS2的β-基酸盐 (BHB) 降解EZH2,而BHB饮料显示出对侵袭性前列腺癌的治疗潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 代谢调节 代谢调节 代谢调节 代谢调节
背景情况:
- 增强Zeste同源2 (EZH2) 是一种氨酸甲基转移酶,在侵袭性癌症中经常被上调.
- 代谢重编程对癌症进展至关重要,但EZH2在癌症代谢中的作用尚不清楚.
研究的目的:
- 研究EZH2与癌症代谢之间的关系,特别关注前列腺癌和乳腺癌中的HMGCS2.
- 探索针对侵袭性前列腺癌中EZH2-HMGCS2-BHB轴的治疗潜力.
主要方法:
- 癌症数据集中EZH2和HMGCS2表达之间的相关性分析.
- 在体外和体内实验,以评估由EZH2.2对HMGCS2的表观遗传调节.
- 研究β-甲酸 (BHB) 对EZH2和前列腺癌进展的影响.
- 异种移植模型评估BHB饮料和组合疗法.
主要成果:
- EZH2与HMGCS2负相关,与癌症进展相反相关.
- EZH2在表观遗传上抑制了HMGCS2的表达.
- 过度表达HMGCS2减少瘤发生; BHB通过降解EZH2.2来阻碍前列腺癌的进展.
- 在抵抗割的前列腺癌模型中,BHB饮料显著降低了瘤负担,与恩扎胺和Tazemetostat相结合时效率提高.
结论:
- 在前列腺癌的进展中,EZH2-HMGCS2-BHB调节网络至关重要.
- BHB饮料代表了针对侵袭性前列腺癌的新型治疗策略,特别是在治疗耐药的病例中.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
01:46Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K